Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
NCT02399566
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
300
Enrollment
OTHER
Sponsor class
Conditions
Lung Adenocarcinoma
Interventions
DRUG:
Erlotinib, Pemetrexed
Sponsor
Hunan Province Tumor Hospital